Double-blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients.
Nomifensine maleate in doses of 100-200 mg/day was compared to placebo in a double-blind study of 50 moderately to severely depressed outpatients seen in a private practice. Efficacy ratings over the 28-day treatment period revealed significant improvement in the nomifensine group on the Hamilton Depression Rating Scale and Clinical Global Impressions, as well as the Self-Rating Symptom Scale, Brief Psychiatric Rating Scale, and Hamilton Anxiety Scale. These differences in favor of nomifensine were seen as early as Day 7 of treatment and were generally consistent throughout the trial. No clinically meaningful changes in vital signs or laboratory values were found over the course of treatment. Only one side effect, a pruritic rash in one patient, was directly attributable to active drug treatment. The CGI Therapeutic Index revealed a very favorable ratio of clinical benefit to side effects for nomifensine maleate.